The Comirnaty vaccine, which is the first to be approved in the Thailand for the age group, will be given in two 10 microgram doses, 21 days apart, the drug regulator said in a statement.
Pfizer says the protection provided by two doses of its anti-COVID-19 vaccine against previous strains will match that provided by three doses of its coronavirus vaccine against the Omicron variant.
The new order, allowing inbound passengers from South Africa, Nigeria and India to Dubai, will be effective from June 23 onwards.
The study also shows that levels of these antibodies that are able to recognise and fight the virus are lower with increasing age, and that levels decline over time, providing additional evidence in support of plans to deliver a booster dose to vulnerable people.
“The data showed that the Pfizer-BioNTech COVID-19 vaccine demonstrated high efficacy consistent with that observed in the adult population,” the health ministry said in a statement, adding “its safety profile is also consistent with the known safety profile in the adult population”.
Sri Lanka is the first country in South Asia to approve the Pfizer vaccine. It has also approved Russia's Sputnik and China's Sinopharm vaccines for emergency use.
The German firm's CEO Ugur Sahin told Der Spiegel weekly that it was "in the final stretches" of preparing its submission for European regulatory approval.
Countries in Europe and Asia, as well as South Africa, are limiting or halting use of AstraZeneca's shot over safety concerns. Rollout of J&J's one-shot vaccine was paused in the United States and Europe this week over a handful of cases of very rare but dangerous blood clots in the brain, much like AstraZeneca's safety issue.
US pharmaceutical giant Pfizer and BioNTech, a smaller German biotech firm, joined forces on April 9, 2020, as the world reeled from the pandemic, with deaths soaring and nations under lockdown.
No cases of the disease were observed in South Africa during the phase-three trial study among participants who had received their second dose, the companies said in a statement.
The pharmaceutical giant's jab was approved by European Union regulators in mid-March, following approval of vaccines made by Pfizer-BioNTech, Moderna and AstraZeneca.
The agency offered good news to grandparents who have refrained from seeing children and grandchildren for the past year, saying that fully vaccinated people may visit indoors with unvaccinated people from a single household so long as no one among the unvaccinated is at risk for severe disease if infected with the coronavirus.
The Pfizer-BioNTech vaccine was the first of three so far to be approved for use in the EU, which has faced strong criticism for a slow start to its vaccination campaign compared with countries such as Israel, Britain and the United States. The other two EU-approved vaccines are from Moderna and AstraZeneca.
Prior to COVID-19 pandemic, India had been producing 60 percent of the world's vaccines for various diseases at an affordable rate.
The update by the Amsterdam-based European Medicines Agency followed reports that dozens of mainly elderly people had died in Norway and other European countries after receiving a first shot of the vaccine.
In a statement, the two companies said the "small differences" detected in tests comparing the original virus and the recent versions "are unlikely to lead to a significant reduction in the effectiveness of the vaccine".
In the initial phase, India will inoculate about one crore healthcare workers. This will be followed by two crore frontline workers, police, armed forces, municipal workers, revenue staff and others. In the third phase, 27 crore people above 50 years of age and those with co-morbidities.
The research team led by BioNTech Chief Executive Officer Ugur Sahin has said the result of the study proves it is very unlikely that the UK variant viruses will be able to dodge the Pfizer COVID-19 vaccine.
Both Pfizer and BioNTech are coordinating with the Norwegian drugs regulator to ascertain the cause behind the deaths of the 23 elderly persons and the former has said that the incident is not alarming and “in line with expectations."
Last week, the Brazil's Butantan Institute had said that the efficacy rate of CoronaVac was 78 percent and claimed to offer total protection against severe cases of the disease.
The airport at Pune, where the Serum Institute is based, is undergoing runway resurfacing. Pharma clusters around Bengaluru and Chennai are serviced from respective airports but the rest have one challenge or the other.